Aurobindo Pharma gets USFDA EIR for Andhra Pradesh facility

The USFDA classified the inspection outcome as 'Voluntary Action Indicated' (VAI) and confirmed that the inspection has been closed.

The USFDA had inspected the facility from 8 December to 17 December 2025, following which a Form 483 with five observations was issued at the end of the inspection.

Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services.

The company's consolidated net profit rose 7.6% to Rs 910.29 crore on a 9% increase in net sales to Rs 8,604.51 crore in Q3 FY26 over Q3 FY25.

Shares of Aurobindo Pharma shed 0.95% to Rs 1,199.85 on the BSE.

Powered by Capital Market - Live News